Adalimumab Effective in JIA-Associated Uveitis Unresponsive to Methotrexate
Adalimumab was well tolerated and associated with persistent uveitis improvement in most cases.
Uveitis
Adalimumab Demonstrated Superior Efficacy Over Standard of Care in Refractory Uveitis
These results indicate superiority of adalimumab vs standard of care in the treatment of severe uveitis cases.
Abnormal Chest Radiograph in Uveitis Often Sarcoidosis
Patients with panuveitis more often had biopsy-confirmed sarcoidosis than those with other anatomical locations of uveitis (20% vs 4%).
Systemic Therapy Associated With Improved Visual Acuity in Uveitis
At seven-year follow-up, visual acuity was better with systemic therapy than with intravitreous fluocinolone acetonide implants.
MTX + Adalimumab Effective in JIA-Associated Uveitis
In children with active juvenile idiopathic arthritis, the treatment combination controls eye inflammation.
Uveitis Risk Higher Among Patients With Psoriasis
Patients with severe psoriasis and those with mild psoriasis and concomitant psoriatic arthritis have an increased risk of uveitis.
Etanercept May Increase Risk of Anterior Uveitis in Ankylosing Spondylitis
Researchers examined whether different TNF inhibitors were associated with different rates of anterior uveitis in patients with ankylosing spondylitis undergoing treatment with adalimumab, etanercept, or infliximab.
Tocilizumab Highly Effective in Refractory Juvenile Idiopathic Arthritis-associated Uveitis
Tocilizumab therapy showed rapid improvement in ocular parameters for uveitis in juvenile idiopathic arthritis patients.
New Uveitis Disease Activity Index Developed By Multidisciplinary Group
Uveitis may be the main source of the primary disease’s symptoms, which indicates the importance of interdisciplinary collaboration between ophthalmologists and rheumatologists in evaluating and treating such patients.
ADA Dosed Weekly Safe in Pediatric JIA, Chronic Uveitis
Most commonly used to treat chronic uveitis, weekly adalimumab was linked to a positive clinical response in 93% of patients.
- Loading...
Loading...
Next post in ACR 2016 Coverage
Loading... 
Loading...